MedTrace Logo

Cefixime Clinical Trial

NCT04958122 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-05-04

No results posted yet for this study

Summary

This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.

Conditions

  • Syphilis
  • Human Immunodeficiency Virus

Interventions

DRUG

Cefixime 400mg

Oral cefixime 400 mg, one capsule, twice a day for 10 days

DRUG

benzathine penicillin

Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU

Sponsors & Collaborators

  • AIDS Healthcare Foundation

    collaborator OTHER

  • Universidad Peruana Cayetano Heredia

    collaborator OTHER

  • University of Southern California

    lead OTHER

Principal Investigators

  • Jeffrey D Klausner, MD MPH · University of Southern California

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-20
Primary Completion
2027-01-01
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04958122 on ClinicalTrials.gov